<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02842983</url>
  </required_header>
  <id_info>
    <org_study_id>esmolol sepsis</org_study_id>
    <nct_id>NCT02842983</nct_id>
  </id_info>
  <brief_title>Pilot Study: Echocardiographic and Hemodynamic Effects of Esmolol in Septic Shock Patients</brief_title>
  <official_title>Pilot Study: Echocardiographic and Hemodynamic Effects of Esmolol in Septic Shock Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking Union Medical College Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking Union Medical College Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      After initial hemodynamic stabilization, 36 septic shock patients with heart rate &gt; of 90 bpm
      and requiring norepinephrine to maintain mean arterial pressure (MAP) more than 65 mmHg will
      be randomised into two groups, esmolol group and control group. Patients allocated to esmolol
      group will receive a continuous esmolol infusion to maintain a lowering of heart rate of 10%.
      Norepinephrine will be titrated to achieve a MAP more than 65 mmHg. To investigate myocardial
      performance, the investigators will assess Tissue Doppler imaging by echocardiography and
      hemodynamic measures. Data will be obtained at baseline ,after esmolol infusion once achieved
      the predefined heart rate threshold and 72hours after esmolol infusion.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      primary outcome were determined according to our previous study of tissue doppler.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2014</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Echocardiographic assessment of heart function</measure>
    <time_frame>over a period of 72 hrs</time_frame>
    <description>peak systolic velocity measured at the mitral annulus decreased 30% compared with control group</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effects on vasopressor requirement</measure>
    <time_frame>over a period of 72 hrs</time_frame>
    <description>Dosage of norepinephrine increased 100% compared with control group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>90-day hospital mortality</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Shock, Septic</condition>
  <arm_group>
    <arm_group_label>Esmolol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After, at least six hours of hemodynamic optimization, patients with a hyperdynamic shock received a conventional management with a continuous infusion of Esmolol titrated to gain a 10% reduction in heart rate. This infusion is maintained for 72 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients received conventional management of septic shock</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Esmolol</intervention_name>
    <description>conventional management plus esmolol infusion</description>
    <arm_group_label>Esmolol</arm_group_label>
    <other_name>beta blockers</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  septic shock

          -  fluid optimization

          -  with a cardiac index &gt; 3 l/min/m2

          -  Heart Rate &gt;90 /min

        Exclusion Criteria:

          -  Cardiogenic shock

          -  Bradycardia

          -  History of Severe Asthma

          -  Indications against Esmolol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yong-tai Liu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking Union Medical College Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yong-tai Liu, MD</last_name>
    <phone>+861069155068</phone>
    <email>ataiever@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Li Weng, MD</last_name>
    <phone>+861069154035</phone>
    <email>wengli@pumch.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yong-tai Liu, MD</last_name>
      <phone>+861069155068</phone>
      <email>ataiever@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 14, 2016</study_first_submitted>
  <study_first_submitted_qc>July 22, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 25, 2016</study_first_posted>
  <last_update_submitted>July 22, 2016</last_update_submitted>
  <last_update_submitted_qc>July 22, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 25, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Esmolol</keyword>
  <keyword>Hypotension</keyword>
  <keyword>Shock, Septic</keyword>
  <keyword>Sepsis</keyword>
  <keyword>Systemic Inflammatory Response Syndrome</keyword>
  <keyword>Adrenergic beta-1 Receptor Antagonists</keyword>
  <keyword>Adrenergic Antagonists</keyword>
  <keyword>Pharmacologic Actions</keyword>
  <keyword>Physiological Effects of Drugs</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Shock</mesh_term>
    <mesh_term>Shock, Septic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esmolol</mesh_term>
    <mesh_term>Adrenergic beta-1 Receptor Antagonists</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>There is not a plan to share individual participant data.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

